Ethinyl Estradiol

Hormone Therapy
DB00977
Approved Indication

For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.

3 Targets
0 Resistance Mutations
0 References
4X1F Structure Loaded
3D Structure PDB: 4X1F
Switch structure: RCSB ↗
Mechanism of Action

Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

Details
DrugBank ID DB00977 ↗
Approval Date 1974-12-27
Molecular Weight 296.4034 g/mol
Drug Class Hormone Therapy
ATC Codes G03AA04, G03AA03, G03AB07, G03AA08, G03AA10, G03AA11, G03AB01, G03AA09, G03AB05, G03CA01, G03AB03, L02AA03, G03AB02, G03AA01, G03AB04, G03AA12, G03AA05, G03AA15, G03AB06, G03AA07, G03AA02, G03AA13, G03AA06, G03AA16
Synonyms 17-ethinyl-3,17-estradiol, 17-ethinyl-3,17-oestradiol, 17-ethinylestradiol
SMILES
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
ADMET Profile
Computing properties…